ClinicalTrials.gg
CompletedNCT07570043RESW101Updated Nov 17, 2026

A Study to Evaluate the Efficacy of a Postbiotic Supplement on Menopausal Symptoms in Premenopausal Women

An interventional study of Supplement and Placebo in Perimenopause, Menopausal Symptoms and Menopause-Related Quality of Life, sponsored by Able Biolabs, LLC. Completed at 1 site in United States. Open to female participants aged 35 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Able Biolabs, LLC · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
35 Years to 55 Years
Sex
Female
01

Study summary

The goal of this consumer health study is to evaluate the effect of resW™ Perimenopause Postbiotic on menopausal symptom severity, menopause-related quality of life, and selected microbiome-related outcomes in generally healthy perimenopausal women aged 35 to 55 years.

Participants will be randomized to receive either the active supplement or placebo daily for 4 weeks. Participants will complete electronic questionnaires at baseline and during the study. A predefined subset of participants will also complete stool and vaginal sample collection at baseline and Week 4.

Read the detailed description

This is a randomized, double-blind, placebo-controlled, parallel-group consumer health study evaluating the effect of resW™ Perimenopause Postbiotic in generally healthy perimenopausal women aged 35 to 55 years.

Eligible participants will be randomized in a 1:1 ratio to receive either resW™ Perimenopause Postbiotic or placebo for 4 weeks. Participants will take 2 capsules daily and complete electronic study questionnaires through the Chloe app. Menopausal symptom severity and menopause-related quality of life will be assessed using the Greene Climacteric Scale and Cervantes Short Form at baseline and Week 4, with an interim Greene Climacteric Scale assessment at Week 2.

A predefined microbiome substudy subset of approximately 20 participants will complete stool and vaginal sample collection at baseline and Week 4. These samples will be used to evaluate exploratory changes in stool microbiome composition, vaginal microbiome composition, and vaginal pH.

Safety and tolerability will be monitored throughout the study through adverse event reporting, compliance tracking, and participant-reported feedback.

02

Conditions studied

  • Perimenopause
  • Menopausal Symptoms
  • Menopause-Related Quality of Life

Keywords

  • Perimenopause
  • Menopausal Symptoms
  • Postbiotic
  • Gut Microbiome
  • Women's Health
  • Hormonal Balance
  • Menopause
  • Vaginal Microbiome
  • Greene Climacteric Scale
  • Cervantes Short Form
  • Dietary Supplement
  • Microbiome
  • Non-hormonal Support
  • Quality of Life
03

In context

Lead sponsor

Able Biolabs, LLC is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide voluntary, signed, and dated .
  • Female, aged 35 to 55 years, inclusive.
  • Currently experiencing perimenopausal symptoms, such as hot flashes, mood changes, sleep disturbance, or irregular cycles.
  • In generally good health as determined by self-reported medical history.
  • Agree to maintain existing diet, exercise, and lifestyle patterns throughout the study period.
  • Able and willing to comply with all study procedures, including electronic consent, app-based data entry, and study questionnaires.
  • Participants selected for the microbiome substudy must be willing to complete stool and vaginal sample collection.
  • Females of must agree to use a medically acceptable form of during the study.
  • Agree to refrain from taking other probiotic, prebiotic, postbiotic, hormonal, or menopause-support supplements during the study.
  • Have reliable internet or smartphone access.

Exclusion criteria

Exclusion Criteria:

  • Currently pregnant, planning to become pregnant, or breastfeeding.
  • History or current diagnosis of gynecologic disorders or other conditions affecting hormonal balance.
  • Current or recent use of hormone replacement therapy or hormonal medications.
  • History of unstable or newly diagnosed cardiovascular, hepatic, renal, or significant metabolic disorders.
  • Known gastrointestinal disease or condition affecting absorption or metabolism.
  • Known allergy or sensitivity to any ingredient in the study supplement.
  • Current participation in another clinical study involving an product or device, or participation in such a study within the past 30 days.
  • Any other medical or psychiatric condition that, in the opinion of the investigator or study team, could interfere with study participation, compliance, or interpretation of study results.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Other: Placebo

  • Experimental
    Supplement

    Dietary Supplement: Supplement

Interventions

  • Dietary supplementSupplement

    L. plantarum RSB11® HI (Postbiotic), Black Cohosh (Actaea racemosa) Extract - 40 mg, Chasteberry (Vitex agnus-castus) Extract - 40 mg, L-Theanine - 200 mg, Magnesium (as Glycinate) - 400 mg, Vitamin D3 (15 μg), Vitamin B6 (2 mg), Vitamin B12 (100 μg)

  • OtherPlacebo

    Microcrystalline cellulose, magnesium stearate, silica, HPMC capsule. Visually and tactilely identical to active.

06

What researchers measure

Primary outcomes

  1. Change in Greene Climacteric Scale total score from baseline to Week 4

    Change from baseline to Week 4 in the Greene Climacteric Scale total score. The Greene Climacteric Scale is a 21-item questionnaire assessing climacteric symptoms. Total scores range from 0 to 63, with higher scores indicating greater climacteric symptom severity, which is a worse outcome.

    Time frame: Baseline to Week 4

  2. Changes in gut microbiota composition associated with hormonal health

    Change from baseline to Week 4 in gut microbiota composition assessed using stool sample microbiome sequencing. Gut microbiota composition will be evaluated by measures including microbial taxonomic relative abundance and diversity metrics derived from sequencing data. This outcome will assess changes in the composition of bacterial taxa in stool samples associated with hormonal health.

    Time frame: 4 weeks

  3. Change in Cervantes Short Form total score from baseline to Week 4

    Change from baseline to Week 4 in the Cervantes Short Form Scale total score. The Cervantes Short Form Scale is a validated menopause-specific quality-of-life questionnaire assessing menopause-related quality of life across physical, psychological, and aging-related domains. Total scores range from 0 to 100, with higher scores indicating poorer menopause-related quality of life, which is a worse outcome.

    Time frame: Baseline to Week 4

Secondary outcomes

  1. Change in stool microbiome alpha diversity from baseline to Week 4

    Change from baseline to Week 4 in stool microbiome alpha diversity, assessed using diversity indices such as the Shannon diversity index, Simpson diversity index, or observed amplicon sequence variants/species richness, in participants enrolled in the microbiome substudy.

    Time frame: Baseline to Week 4

  2. Change in stool microbial taxonomic composition from baseline to Week 4

    Change from baseline to Week 4 in the relative abundance of stool microbial taxa, assessed using stool sample microbiome sequencing, in participants enrolled in the microbiome substudy.

    Time frame: Baseline to Week 4

  3. Change in vaginal microbiome alpha diversity from baseline to Week 4

    Change from baseline to Week 4 in vaginal microbiome alpha diversity, assessed using diversity indices such as the Shannon diversity index, Simpson diversity index, or observed amplicon sequence variants/species richness, in participants enrolled in the microbiome substudy.

    Time frame: Baseline to Week 4

  4. Change in relative abundance of vaginal microbial taxa from baseline to Week 4

    Change from baseline to Week 4 in the relative abundance of vaginal microbial taxa, including Lactobacillus species and bacterial vaginosis-associated taxa, assessed using vaginal sample microbiome sequencing, in participants enrolled in the microbiome substudy.

    Time frame: Baseline to Week 4

  5. Change in vaginal pH from baseline to Week 4

    Change from baseline to Week 4 in vaginal pH, measured from vaginal samples using a pH test method, in participants enrolled in the microbiome substudy. Vaginal pH is measured on a continuous scale, with higher values indicating greater vaginal alkalinity.

    Time frame: Baseline to Week 4

07

Study locations

1 site
  • Able Biolabs LLC
    Dallas, Texas 75247, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2026 to primary completion in May 2026, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2026
First posted
May 6, 2026
StartActual
Mar 4, 2026
Primary completionActual
May 15, 2026
CompletionActual
May 27, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: conditions and arm descriptions
1 update, last Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Minor edits only
    + 2 other changes: conditions and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07570043
Lead sponsor
Able Biolabs, LLC
Responsible party
Sponsor
First posted
May 6, 2026
Start date
Mar 4, 2026
Primary completion
May 15, 2026
Completion
May 27, 2026
Last update
Nov 17, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion